{
    "nct_id": "NCT02967692",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "Part 1: Safety run-in\n\n* Subjects with uveal or mucosal melanoma\n* Any history of CNS metastases\n* Prior systemic anti-cancer treatment for unresectable or metastatic melanoma\n* Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollmen\n* Radiation therapy within 4 weeks prior to start of study treatment\n* Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment\n\nParts 2 & 3: Biomarker cohort & double-blind, randomized, placebo-controlled part\n\n* Subjects with uveal or mucosal melanoma\n* Prior systemic anti-cancer treatment for unresectable or metastatic melanoma\n* Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollment\n* Radiation therapy within 4 weeks prior to start of study treatment\n* Clinically active cerebral melanoma metastasis.\n* Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment\n\nOther protocol-defined Inclusion/Exclusion may apply.",
    "miscellaneous_criteria": "Inclusion criteria Part 1: Safety run-in\n\n* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n* Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase (ALT) < 2.5× ULN\n* Measurable disease according to RECIST 1.1\n* ECOG performance status ≤ 1\n\nPart 2: Biomarker cohort\n\n* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n* At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection\n* Measurable disease according to RECIST 1.1\n* ECOG performance status ≤ 2\n\nPart 3: Double-blind, randomized, placebo-controlled part\n\n* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation\n* ECOG performance status ≤ 2\n* Measurable disease according to RECIST 1.1"
}